STENTYS: Results of Self-Apposing Sirolimus-Eluting Stent Trial Published in EuroIntervention

APPOSITION IV trial demonstrated superior apposition and faster healing than with conventional stents

PRINCETON, N.J. and PARIS ., STENTYS, a medical technology company commercializing the world's first and only Self-Apposing® coronary stent, today announces that the results of the APPOSITION IV trial, which compared the STENTYS SelfApposing Sirolimus-eluting coronary stent to the Medtronic Resolute® stent in patients presenting with ST-segment elevation myocardial infarction (STEMI), were published in the February issue of EuroIntervention, the official Journal of EuroPCR and the European Association of Percutaneous Cardiovascular Interventions (EAPCI).

The clinical study demonstrated that stent apposition was statistically better in the STENTYS group than the balloon-expandable group at 4 months, with a greater percentage of STENTYS stents fully covered, a surrogate marker of healing. At 9 months, the use of STENTYS SES showed no reduction in artery lumen diameter with a near perfect strut coverage.

The authors wrote: “The absence of any reduction in minimum lumen diameter combined with a very high rate of strut coverage is a good indicator of long-term safety for the STENTYS SES”. They added: “Another interesting finding is the augmented lumen size in the STENTYS arm: with the addition of sirolimus elution, this benefit is extended to four and nine months.”

Gonzague Issenmann, Chief Executive Officer and co-founder of STENTYS, commented: “The SelfApposing Sirolimus-eluting stent, which is now commercialized with its new delivery catheter under the brand Xposition S, is the only stent that can guarantee complete and continuous apposition even when treating heart attack patients. We believe this publication will reinforce the adoption of our technology among cardiologists looking for the optimal stent solution for their patients.”

Source: STENTYS